CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK 1509745 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 107.8M shares as of Aug 10, 2026 (10-Q). Share count fell from 119.4M to 25.6M between May 10, 2023 and Aug 9, 2023, a pattern consistent with a reverse split (roughly 1-for-5); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| October2025 Pre Funded Warrants | 80.8M | $0.001 | — | — |
| October2025 Common Warrants | 76.0M | $0.5335 | — | — |
| October2025 Private Placement | 72.0M | $0.5335 | — | — |
| March2020 Coverage Warrants | 1.9M | $21.1 | — | — |
| January2023 Common Stock Warrants | 6,530 | $6.78 | — | — |
| Warrants Exercisable On23rd January2017 | 5,450 | $0.1 | — | — |
| January2023 Series X Preferred Stock Warrants | 443 | $6.78 | — | — |
| Warrants2019 | not tagged | $19.5 | — | — |
| March2020 Pre Funded Warrants | not tagged | $0.001 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 158.7M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $6.78 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $3.4M as of Dec 31, 2018.
Down-round (price protection) accounting has been tagged in this filer’s XBRL: some instrument carries repricing protection. Which tranche requires reading the exhibits.
Rough fully diluted estimate: 266.4M = 107.8M O/S + 158.7M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 12, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 107.8M | Aug 10, 2026 |
| + October2025 Pre Funded Warrants (if exercised) | 80.8M | Jun 30, 2026 |
| + October2025 Common Warrants (if exercised) | 76.0M | Jun 30, 2026 |
| + October2025 Private Placement (if exercised) | 72.0M | Oct 31, 2025 |
| + March2020 Coverage Warrants (if exercised) | 1.9M | Jun 30, 2026 |
| + January2023 Common Stock Warrants (if exercised) | 6,530 | Jan 31, 2023 |
| + Warrants Exercisable On23rd January2017 (if exercised) | 5,450 | Jun 30, 2026 |
| + January2023 Series X Preferred Stock Warrants (if exercised) | 443 | Jan 31, 2023 |
| Fully diluted estimate | 338.4M | +214.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 2 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full CYPH workspace